CA
MYGN icon

Commerzbank Aktiengesellschaft’s Myriad Genetics MYGN Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-15,000
Closed -$511K – 1202
2014
Q4 		$511K Buy
+15,000
New +$532K ﹤0.01% 1004

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Commerzbank Aktiengesellschaft's MYGN Position: Q4 2019 in Review

Commerzbank Aktiengesellschaft sold out of Myriad Genetics (MYGN) in Q4 2019, closing a stake of 20,000 shares — an estimated $573K sold.

Commerzbank Aktiengesellschaft first reported a position in MYGN in Q2 2013 and held it in 22 quarters. The position peaked at $1.01M in Q1 2016. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

  • Commerzbank Aktiengesellschaft reported no remaining Myriad Genetics position as of Q4 2019 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 20,000 Myriad Genetics shares in Q4 2019, an estimated $573K.
  • Commerzbank Aktiengesellschaft first reported a position in Myriad Genetics in Q2 2013 and held it in 22 quarters.
  • Commerzbank Aktiengesellschaft's Myriad Genetics position peaked at $1.01M in Q1 2016.
  • 227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q4 2019, filed 17 Jan 2020.